Paul Taylor

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò et al. · The Lancet Oncology · 2017 · 422 citations

Surgical Oncology, Malignant Disease, Relapsed Malignant Mesothelioma +8

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Giorgio V. Scagliotti, Rabab Gaafar, Anna K. Nowak et al. · The Lancet Respiratory Medicine · 2019 · 164 citations

Placebo-controlled Phase 3, Pleural Disease, Anti-cancer Agent +6

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Federica Grosso, Nicola Steele, Silvia Novello et al. · Journal of Clinical Oncology · 2017 · 138 citations · Full text

Cancer Management, Pathology, Metronomic Chemotherapy +16

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study

Dean A. Fennell, Paul Baas, Paul Taylor et al. · Journal of Clinical Oncology · 2019 · 123 citations

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Marjorie G. Zauderer, Peter W. Szlosarek, Sylvestre Le Moulec et al. · The Lancet Oncology · 2022 · 119 citations

Ezh2 Inhibitor Tazemetostat, Malignant Disease, Medicine +7